| Identification | Back Directory | [Name]
Pyroxamide | [CAS]
382180-17-8 | [Synonyms]
NSC 696085
Pyroxamide
Pyroxamide
PyroxaMide (NSC 696085)
Pyroxamide ISO 9001：2015 REACH
N-Hydroxy-N'-3-pyridinyloctanediamide
N1-Hydroxy-N8-3-pyridinyl-octanediamide
n-hydroxy-n'-(pyridin-3-yl)octanediamide
N1-Hydroxy-N8-(pyridin-3-yl)octanediamide
Octanediamide, N1-hydroxy-N8-3-pyridinyl-
PYROXAMIDE, N-HYDROXY-N'-3-PYRIDINYLOCTANEDIAMIDE
2-[1-carbaMoyl-N-(2H-pyran-2-yl)forMaMido]-N-hydroxy-N'-(pyridin-3-yl)octanediaMide
382180-17-8; NSC-696085; N-HYDROXY-N'-3-PYRIDINYLOCTANEDIAMIDE; N-HYDROXY-N'-(PYRIDIN-3-YL)OCTANEDIAMIDE; NSC696085; NSC 696085 | [Molecular Formula]
C13H19N3O3 | [MDL Number]
MFCD13194970 | [MOL File]
382180-17-8.mol | [Molecular Weight]
265.31 |
| Hazard Information | Back Directory | [Description]
Pyroxamide is an inhibitor of histone deacetylases (HDACs), including HDAC1 (IC50 = 0.1-0.2 μM). It induces growth suppression and cell death of certain types of cancer cells in culture. | [Uses]
Pyroamide is a histone decetylase inhibitor (HDCi), a novel class of anti-neoplastic agent that acts by enhancing acetylation of histones, promoting uncoiling of chromatin and activation of genes imp
licated in the regulation of cell survival such as poliferation, differentiation and apoptosis. Pyroamide is known to potently inhibits affinity purified HDAC1. Also inhibits the growth of tumor cells
in vitro and in vivo. Induces p21/WAF1 expression in tumor cells. | [Uses]
Pyroxamide is an inhibitor of histone deacetylases (HDACs), including HDAC1 (IC50 = 0.1-0.2 μM). It induces growth suppression and cell death of certain types of cancer cells in culture. | [Definition]
ChEBI: N'-hydroxy-N-(3-pyridinyl)octanediamide is an aromatic amide. | [IC 50]
HDAC1: 100 nM (ID50) | [storage]
Store at -20°C | [References]
[1]. butler lm, webb y, agus db, et al. inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. clin cancer res, 2001, 7(4): 962-970.
[2]. kutko mc, glick rd, butler lm, et al. histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. clin cancer res, 2003, 9(15): 5749-5755. |
|
|